W.H. Cornerstone Investments Inc. Purchases 268 Shares of Thermo Fisher Scientific Inc. $TMO

W.H. Cornerstone Investments Inc. raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.4% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,886 shares of the medical research company’s stock after purchasing an additional 268 shares during the period. Thermo Fisher Scientific makes up about 1.0% of W.H. Cornerstone Investments Inc.’s investment portfolio, making the stock its 21st biggest holding. W.H. Cornerstone Investments Inc.’s holdings in Thermo Fisher Scientific were worth $1,576,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Flossbach Von Storch SE increased its holdings in Thermo Fisher Scientific by 93.0% during the second quarter. Flossbach Von Storch SE now owns 2,727,021 shares of the medical research company’s stock worth $1,105,698,000 after buying an additional 1,314,182 shares during the last quarter. Nuveen LLC acquired a new stake in Thermo Fisher Scientific in the first quarter valued at approximately $532,360,000. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of Thermo Fisher Scientific by 29.5% during the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,257,424 shares of the medical research company’s stock worth $915,295,000 after purchasing an additional 514,399 shares during the period. EdgePoint Investment Group Inc. acquired a new stake in Thermo Fisher Scientific during the 1st quarter worth about $172,139,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Thermo Fisher Scientific by 13.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company’s stock valued at $1,368,859,000 after purchasing an additional 329,974 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 10,225 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $571.62, for a total value of $5,844,814.50. Following the sale, the vice president owned 14,145 shares of the company’s stock, valued at approximately $8,085,564.90. The trade was a 41.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction on Friday, October 24th. The stock was sold at an average price of $574.15, for a total value of $229,660.00. Following the transaction, the executive vice president directly owned 21,152 shares in the company, valued at $12,144,420.80. This represents a 1.86% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 46,645 shares of company stock worth $25,825,699 over the last three months. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Trading Up 0.9%

Shares of TMO traded up $5.33 during mid-day trading on Thursday, reaching $593.35. The stock had a trading volume of 251,029 shares, compared to its average volume of 2,356,608. The business’s fifty day moving average is $524.35 and its 200 day moving average is $465.87. The firm has a market cap of $222.93 billion, a price-to-earnings ratio of 34.38, a P/E/G ratio of 3.27 and a beta of 0.82. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, topping the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The business had revenue of $11.12 billion during the quarter, compared to the consensus estimate of $10.90 billion. During the same quarter in the previous year, the firm posted $5.28 earnings per share. The company’s quarterly revenue was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific declared that its board has authorized a share buyback program on Thursday, November 6th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical research company to reacquire up to 2.4% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s leadership believes its shares are undervalued.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.94%.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Hsbc Global Res downgraded Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 24th. Robert W. Baird raised their price objective on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a research note on Thursday, July 24th. Weiss Ratings reissued a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Tuesday, October 14th. Redburn Partners set a $580.00 price target on shares of Thermo Fisher Scientific in a report on Wednesday, October 8th. Finally, Leerink Partners boosted their price objective on shares of Thermo Fisher Scientific from $545.00 to $580.00 and gave the company an “outperform” rating in a research report on Wednesday, October 22nd. Nineteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average target price of $601.65.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.